BRIEF-Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101

Jade Biosciences, Inc.

Jade Biosciences, Inc.

JBIO

0.00

June 1 (Reuters) - Jade Biosciences Inc JBIO.O:

  • JADE BIOSCIENCES - JADE101 SUSTAINS ~70% IGA REDUCTION AT 12 WEEKS AFTER SINGLE DOSE

  • JADE BIOSCIENCES - JADE101 WELL-TOLERATED ACROSS ALL EVALUATED DOSES

  • JADE BIOSCIENCES - JADE101 PROJECTS >70% IGA REDUCTION WITH EVERY-12-WEEK MAINTENANCE DOSING

  • JADE BIOSCIENCES - PHASE 2 TRIAL IN IGA NEPHROPATHY UNDERWAY, INTERIM DATA EXPECTED IN 2027

  • JADE BIOSCIENCES - PHASE 3 REGISTRATIONAL TRIAL EXPECTED TO INITIATE IN FIRST HALF OF 2027

Source text: ID:nGNXbRgxKF

Further company coverage: JBIO.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.